The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Open accessAbstract
To convert the values for low-density lipoprotein (LDL) cholesterol to millimoles per liter, multiply by 0.02586.† Included in this category is the number of patients who underwent randomization and received at least one dose of a study drug.‡ Patients who were enrolled in phase 2 parent trials and who agreed to participate in the extension study were enrolled in OSLER-1.§ Patients who were enrolled in phase 3 parent trials and who agreed to participate in the extension study were enrolled in OSLER-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with one agent showing benefit only among patients who had a baseline LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter). 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both our trial and the SPIRE trial showed a more prominent absolute reduction in the risk of cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter. 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, there were little more than 100 events in these studies combined.”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, exploratory data from longer-term follow-up in phase 2 and phase 3 trials of PCSK9 inhibitors showed significant reductions in cardiovascular outcomes.9,10”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
In the citing paper
“No major effect on HDL-C has been reported, while TGs may increase in some predisposed patients [274].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“At the top daily dose of 24 g of cholestyramine, 20 g of colestipol, or 4.5 g of colesevelam, a reduction in LDL-C of 18-25% has been observed.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and nicotinic acid reduce Lp(a) by ≏ 30%. 115-117”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men. 115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Results in studies with PCSK9 inhibitors that included post-ACS/very high-risk patients were promising 115,116 and definitive outcome studies are awaited.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50e70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Combination therapy using statin and ezetimibe prevents ASCVD incidence in patients with ACS. (Evidence level 1+, recommendation level: B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“The IMPROVE-IT study636) which enrolled ACS subjects (secondary prevention) with controlled LDL-C levels (50–100 mg/dL) under simvastatin treatment, revealed a significantly lower ASCVD incidence in the group for which ezetimibe was added on to simvastatin treatment.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“Regarding the LDL-C management target, the IMPROVE-IT636) study revealed that lowering the LDL-C level to 53.6 mg/dL using statin–ezetimibe combination therapy suppressed cardiovascular events by 6.4% more than the group that had their LDL-C level controlled at 69.5 mg/dL with statins only.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“(10,11).These agents dramatically reduce LDL-C levels over and above statin therapy, with favorable short-term outcomes data up to 18 months (11,12).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Sorted by citations
Items 801–900 of 1,004
Silbernagel, G., Scharnagl, H., Kleber, M. E., Stojaković, T., & März, W. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317693938 · Cited by 12
Management of patients with statin intolerance
Fischer, S., & Julius, U. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.013 · Cited by 12
Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia
Boccara, F., Dent, R. E., Ruilope, L. M., & Valensi, P. E. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0586-8 · Cited by 14
Qiu, C., Zhou, Q., Li, X., Zhang, Z., Zeng, P., Cao, Z., Pan, B., Li, X., & Chen, A. F. (2017) · Medicine · doi:10.1097/md.0000000000008848 · Cited by 12
Altunkeser, B. B., Tunçez, A., Öztürk, B., Tezcan, H., Ateş, M. S., Yılmaz, C., Yalçın, M. U., Aygül, N., & Demır, K. (2019) · Coronary Artery Disease · doi:10.1097/mca.0000000000000715 · Cited by 12
Identifying asymptomatic patients at high-risk for stroke
Gaba, K., & Bulbulia, R. A. (2019) · The Journal of Cardiovascular Surgery · doi:10.23736/s0021-9509.19.10912-3 · Cited by 12
Kloer, H.-U., Belardinelli, R., Ou, R., & Rosenfeldt, F. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.08.017 · Cited by 12
Lipid-Modifying Drugs: Pharmacology and Perspectives
Xu, R.-X., & Wu, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_5 · Cited by 12
Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
Desai, N. R., Wade, R. L., Xiang, P., Pinto, L. A., Nunna, S., Wang, X., Exter, J., Mues, K. E., Habib, M., & Chen, C. (2021) · Clinical Cardiology · doi:10.1002/clc.23600 · Cited by 12
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
FITCHETT, D. H., Goodman, S. G., Leiter, L. A., Lin, P., Welsh, R. C., Stone, J. A., Grégoire, J. C., McFarlane, P. A., & Langer, A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.03.002 · Cited by 12
Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
Shah, S. R., Uddin, M. F., Lateef, N., Dharani, A. M., Shahnawaz, W., Kazi, A. N., & Shah, S. A. (2017) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2017.1340732 · Cited by 11
Sun, H., Li, Z., Song, X., Liu, H., Li, Y., Hao, Y., Teng, T., Liu, J., Liu, J., Zhao, D. H., et al. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuab053 · Cited by 12
Cowie, M., Bozkurt, B., Butler, J., Briggs, A. H., Kubin, M., Jonas, A., Adler, A., Patrick‐Lake, B., & Zannad, F. M. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.020 · Cited by 11
New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets
Wojtasińska, A., Kućmierz, J., Tokarek, J., Dybiec, J., Rodzeń, A., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316735 · Cited by 13
Association between cardiometabolic index and myocardial Infarction: based on NHANES database
Zhang, J., Jiang, J., Zhao, J., Chen, K., Yuan, P., Wang, Y., & Zhang, H. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2460404 · Cited by 11
Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids
Shantha, G., & Robinson, J. G. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.281 · Cited by 11
Self-citationEmerging biologic therapies for hypercholesterolaemia
Pucci, G., Cicero, A. F. G., Borghi, C., & Schillaci, G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1341485 · Cited by 11
Mallya, U. G., Boklage, S., Koren, A., Delea, T. E., & Mullins, C. D. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0590-5 · Cited by 11
Hirai, K., Imamura, S., Hirai, A., Ookawara, S., & Morishita, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072256 · Cited by 11
Grundy, S. M. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_3 · Cited by 14
Okada, T., Miyoshi, T., Doi, M., Nosaka, K., Tsushima, R., Ugawa, S., Takagi, W., Sogo, M., Takahashi, M., & Ito, H. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050153 · Cited by 11
Luo, J., Liao, W., Wang, X., Xu, R., Li, W., Li, W., Liu, K., Huang, K., Ma, Y., Wang, T., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062046 · Cited by 11
Use and role of monoclonal antibodies and other biologics in preventive cardiology
Gencer, B., Laaksonen, R., Buhayer, A., & Mach, F. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14179 · Cited by 11
Decreased serum PCSK 9 levels after ischaemic stroke predict worse outcomes
Liberale, L., Montecucco, F., Casetta, I., Seraceni, S., Trentini, A., Padroni, M., Dallegri, F., Mach, F., Fainardi, E., & Carbone, F. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12692 · Cited by 11
Genética de la cardiopatía isquémica: del conocimiento actual a las implicaciones clínicas
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.02.033 · Cited by 11
Volpe, M., Volpe, R., Gallo, G., Presta, V., Tocci, G., Folco, E., Peracino, A. P., Tremoli, E., & Trimarco, B. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0211-6 · Cited by 11
Punchaichira, T. J., Dey, S. K., Mukhopadhyay, A., Kundu, S., & Thelma, B. K. (2017) · Neurogenetics · doi:10.1007/s10048-017-0519-3 · Cited by 11
Recent advances in the management of transient ischemic attacks
Gomez, C. R., Schneck, M. J., & Biller, J. (2017) · F1000Research · doi:10.12688/f1000research.12358.1 · Cited by 13
Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease
Suh, D., Griggs, S. K., Henderson, E. R., Lee, S.-M., & Park, T. (2017) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1407246 · Cited by 11
Gebauer, K., & Reinecke, H. (2018) · VASA · doi:10.1024/0301-1526/a000689 · Cited by 11
Secondary prevention of cardiovascular diseases: current state of the art
Hasenfuss, G. P. (2018) · Kardiologia Polska · doi:10.5603/kp.a2018.0198 · Cited by 11
PCSK9: from molecular biology to clinical applications
Malo, J., Parajuli, A., & Walker, S. W. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219864379 · Cited by 12
Nishikido, T., & Ray, K. K. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14851 · Cited by 11
Torres, E., Goicoechea, M., Hernández, A., Ferrero, M. L. R., García‐Prieto, A., Macías, N., & Anaya, F. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21752 · Cited by 11
Management of Familial Hypercholesterolemia in Hong Kong
Hu, M., Hooper, A. J., BOCKXMEER, F. M. V., Watts, G. F., Chan, J. C. N., & Tomlinson, B. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.34314 · Cited by 11
MABS: targeted therapy tailored to the patient's need
Miedany, Y. M. E. (2015) · British Journal of Nursing · doi:10.12968/bjon.2015.24.sup16a.s4 · Cited by 11
FH through the retrospectoscope
Thompson, G. R. (2020) · Journal of Lipid Research · doi:10.1194/jlr.tr120001001 · Cited by 11
PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance
Voutyritsa, E., Damaskos, C., Farmaki, P., Kyriakos, G., Diamantis, E., Quiles-Sánchez, L. V., Garmpi, A., Garmpis, N., Patsouras, A., Stelianidi, A., et al. (2021) · In Vivo · doi:10.21873/invivo.12232 · Cited by 11
Kosmas, C. E., Sourlas, A., Bouza, K. V., DeJesus, E., Silverio, D., Montan, P. D., & Guzman, E. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.20 · Cited by 11
Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics
Zhu, B. J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020634 · Cited by 11
Hohenstein, B., Tselmin, S., Bornstein, S. R., & Julius, U. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.012 · Cited by 10
Ma, X., Yan, D., Zhou, C., Shi, Y., Wang, Y., Li, J., Zhong, Q., Li, X., Hu, Y., Liang, W., et al. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2441399 · Cited by 10
Jha, M., Agrawal, S. P., Maheta, D., Bhattacharjee, P., Jain, H., Zacks, J. S., Frishman, W. H., & Aronow, W. S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2511063 · Cited by 10
Ho, V. Q. T., Tran, N. B., Nguyen, N. M. T., Arrighini, G. S., Downes, D., Dandamudi, M., Ferrara, V. Z., Ho, T. H. Q., Walia, H., Barbagelata, A., et al. (2025) · Open Heart · doi:10.1136/openhrt-2025-003490 · Cited by 11
Singh, S. A., Miyosawa, K., & Aikawa, M. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1078731 · Cited by 10
Page, M. M., Hooper, A. J., & Burnett, J. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1129402 · Cited by 10
Stein, E. A. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000242 · Cited by 10
Self-citationRetargeting the management of hypercholesterolemia – focus on evolocumab
Cicero, A. F. G., Colletti, A., & Derosa, G. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s116679 · Cited by 10
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals
Wasserman, S. M., Sabatine, M. S., Koren, M. J., Giugliano, R. P., Legg, J. C., Emery, M. G., Doshi, S., Liu, T., Somaratne, R. M., & Gibbs, J. P. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418774043 · Cited by 10
Self-citationNew and Future Parenteral Therapies for the Management of Lipid Disorders
García, R. R., & Burkle, J. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.01.001 · Cited by 10
Challenges in reducing atherosclerotic inflammation in patients with familial hypercholesterolemia
Montecucco, F., Carbone, F., Liberale, L., & Sahebkar, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319862907 · Cited by 10
Lipid-lowering Therapies in Myositis
Mizus, M. C., & Tiniakou, E. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00942-3 · Cited by 10
Frątczak, A., Polak, K., Szczepanek, M., & Lis‐Święty, A. (2022) · Advances in Dermatology and Allergology · doi:10.5114/ada.2022.118919 · Cited by 10
Iluţ, S., Pîrlog, B. O., Pîrlog, R., Nutu, A. M., Văcăraș, V., & Armean, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810221 · Cited by 11
Qiao, M., Li, Y., Yang, Y., Pang, C.-X., Liu, Y., Bian, C., Wang, L., Chen, X., & Hong, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115047 · Cited by 10
Sindi, A. A. A. (2023) · Journal of Lipids · doi:10.1155/2023/2025490 · Cited by 11
Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia
Whayne, T. F. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0150-3 · Cited by 11
Androulakis, E. S., Zacharia, E. M., Παπαγεωργίου, Ν., Lioudaki, E., Bertsias, D., Charakida, M., Siasos, G., & Tousoulis, D. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170209145622 · Cited by 10
White, C. M. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418769040 · Cited by 10
Navarese, E. P., Kołodziejczak, M. M., Petrescu, A. M., Wernly, B., Lichtenauer, M., Lauten, A., Buffon, A., Wańha, W., Pestrichella, V., Sardella, G., et al. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1474099 · Cited by 10
Lohoff, F. W. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy087 · Cited by 10
Status of PCSK9 Monoclonal Antibodies in Australia
Scherer, D. J., Nelson, A. J., O’Brien, R. C., Kostner, K., Hare, D. L., Colquhoun, D. M., Barter, P. J., Aylward, P. E., Nicholls, S. J., & Watts, G. F. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.04.014 · Cited by 10
Kashiwagi, D., Ebisawa, S., Yui, H., Maruyama, S., Nagae, A., Sakai, T., Kato, T., Saigusa, T., Okada, A., Motoki, H., et al. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01680-3 · Cited by 10
A Single‐Dose Qβ VLP Vaccine against S100A9 Protein Reduces Atherosclerosis in a Preclinical Model
Ortega-Rivera, O. A., Shin, M. D., Moreno‐Gonzalez, M. A., Pokorski, J. K., & Steinmetz, N. F. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200092 · Cited by 10
Lipid Disorders in Children and Adolescents
Daniels, S. R., & Couch, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00025-7 · Cited by 10
The efficacy of anti-PCSK9 antibodies: Results from recent trials
Gouni‐Berthold, I. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.030 · Cited by 10
Mizobe, T., Nakamura, M., Motooka, Y., Ashida, N., & Sugihara, M. (2017) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.10.009 · Cited by 10
Sweetless'n low LDL-C targets for PCSK9 treatment : Figure 1
Gencer, B., & Mach, F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv056 · Cited by 10
Lower might be better – It matters how you get there, and in whom
Robinson, J. G. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw102 · Cited by 10
Self-citationBandaru, M. K., Emmanouilidou, A., Ranefall, P., von der Heyde, B., Mazzaferro, E., Klingström, T., Masiero, M. M., Dethlefsen, O., Ledin, J., Larsson, A. O., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/502674 · Cited by 10
Insight into the role of PCSK9 in glucose metabolism
Xu, J., Wang, T., Shu, H., Shi, S., Tao, L., & Li, J. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117444 · Cited by 11
Wierzbicki, A. S., & Grant, P. S. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-4-353 · Cited by 9
Arca, M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.09.001 · Cited by 9
Shah, P. K., Glueck, C. J., Goldenberg, N., Min, S., Mahida, C., Schlam, I. M., Rothschild, M., Huda, A. N., & Wang, P. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0416-7 · Cited by 9
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Parikh, R. R., Breve, F., Magnusson, P., Behzadi, P., & Pergolizzi, J. V. (2022) · Cureus · doi:10.7759/cureus.25641 · Cited by 10
Ogungbe, O., Grant, J. K., Ayoola, A., Bansah, E. C., Miller, H., Plante, T. B., Sheikhattari, P., Commodore-Mensah, Y. Y., Turkson‐Ocran, R., Juraschek, S. P., et al. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01942-2 · Cited by 9
PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis
Bodapati, A. P., Hanif, A., Okafor, D. K., Katyal, G., Kaur, G., Ashraf, H., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.46605 · Cited by 15
Hummelgaard, S., Hvid, H., Birn, H., Glerup, S., Tom, N., Bilgin, M., Kirchhoff, J. E., & Weyer, K. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00065.2024 · Cited by 10
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 9
Lipid Management in Diabetes with a Focus on Emerging Therapies
Hoe, E., & Hegele, R. A. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.012 · Cited by 9
Promising new therapies for the treatment of hypercholesterolemia
Valerio, M. G., Velayati, A., Jain, D., & Aronow, W. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1148136 · Cited by 9
Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction
Toth, P. P. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.05.028 · Cited by 9
He, X., Zhang, R., Zuo, P.-Y., Liu, Y., Zha, X., Shan, S., & Liu, C. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.10.009 · Cited by 10
Gupta, S. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s83719 · Cited by 9
Gao, J., Wang, H., Xiao, J.-Y., Ren, M., Reilly, K. H., Li, Y., & Liu, Y. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-021951 · Cited by 9
New agents to reduce cholesterol levels: implications for nephrologists
Vecchio, L. D., Baragetti, I., & Locatelli, F. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz013 · Cited by 9
Oren, O., Kludtke, E. L., & Kopecky, S. L. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.08.016 · Cited by 9
Robinson, J. G., Jayanna, M. B., Merz, C. N. B., & Stone, N. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240166 · Cited by 9
Self-citationLiu, Y.-L., Zhou, Z., Gao, M., Ji, G., Huang, C., & Fan, S. (2020) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2020.11.002 · Cited by 9
Aranzulla, T. C., Piazza, S., Ricotti, A., Musumeci, G., & Gaggiano, A. (2021) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29743 · Cited by 9
Zhao, X., Song, L., Wang, Y., Li, J., Zhou, J., Chen, R., Liu, C., Zhou, P., Sheng, Z., Chen, Y., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s334246 · Cited by 9
Schludi, B., Giugliano, R. P., Sabatine, M. S., Raal, F. J., Teramoto, T., Koren, M. J., Stein, E. A., Wang, H., & Monsalvo, M. L. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.05.069 · Cited by 9
Self-citationGhouse, J., Ahlberg, G., Skov, A. G., Bundgaard, H., & OLESEN, M. S. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025361 · Cited by 9
Current and future options in cholesterol lowering treatments
Elis, A. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.02.010 · Cited by 9
Forbes, C. A., Quek, R. G. W., Deshpande, S., Worthy, G., Ross, J., Kleijnen, J., Gandra, S. R., Kassahun, H., Wong, N. D., & Nicholls, S. J. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1162775 · Cited by 9
Toplak, H., Ludvik, B. H., Lechleitner, M., Dieplinger, H., Föger, B., Paulweber, B., Weber, T., Watschinger, B., Horn, S., Wascher, T. C., et al. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0993-x · Cited by 9
Experimental and clinical pharmacology: PCSK9 inhibitors - clinical applications
Schmidli, R. S. (2016) · Australian Prescriber · doi:10.18773/austprescr.2016.061 · Cited by 9
Hyperlipoproteinaemia(a) – apheresis and emerging therapies
Vogt, A. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0083-2 · Cited by 9
Metadata
- Authors
- Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., Scott, R., Koren, M. J., & Stein, E. A.
- Affiliations
- University of Iowa (US)
- Harvard University (US)
- University of the Witwatersrand (ZA)
- University of Cape Town (ZA)
- Houston Methodist (US)
- Amgen (United States) (US)
- Jacksonville Center for Clinical Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1500-1509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4238580056
- Semantic Scholar
- 3a2aa2d61647c779adc7c8fa42c75fb373940128
- Cited by
- 1,509
- References
- 26
- Citations by year
- 2026: 44 · 2025: 54 · 2024: 71 · 2023: 73 · 2022: 88 · 2021: 91 · 2020: 104 · 2019: 148 · 2018: 152 · 2017: 261 · 2016: 277 · 2015: 141
- FWCI
- 279.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- evolocumab, PCSK9 inhibitors, LDL cholesterol lowering, cardiovascular events, lipid-lowering therapy, drug efficacy, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
